HomeCompareAAPGV vs MO

AAPGV vs MO: Dividend Comparison 2026

AAPGV yields 11.51% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $37.4K in total portfolio value· pulled ahead in Year 8
10 years
AAPGV
AAPGV
● Live price
11.51%
Share price
$17.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.8K
Annual income
$2,362.57
Full AAPGV calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — AAPGV vs MO

📍 MO pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAAPGVMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AAPGV + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AAPGV pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AAPGV
Annual income on $10K today (after 15% tax)
$978.14/yr
After 10yr DRIP, annual income (after tax)
$2,008.18/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $23,627.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AAPGV + MO for your $10,000?

AAPGV: 50%MO: 50%
100% MO50/50100% AAPGV
Portfolio after 10yr
$61.4K
Annual income
$16,260.87/yr
Blended yield
26.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

AAPGV
No analyst data
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AAPGV buys
0
MO buys
0
No recent congressional trades found for AAPGV or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAAPGVMO
Forward yield11.51%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$42.8K$80.1K
Annual income after 10y$2,362.57$30,159.17
Total dividends collected$17.5K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: AAPGV vs MO ($10,000, DRIP)

YearAAPGV PortfolioAAPGV Income/yrMO PortfolioMO Income/yrGap
1$11,851$1,150.75$10,570$780.30+$1.3KAAPGV
2$13,955$1,274.51$11,381$1,032.90+$2.6KAAPGV
3$16,334$1,402.61$12,535$1,392.73+$3.8KAAPGV
4$19,012$1,534.36$14,193$1,920.91+$4.8KAAPGV
5$22,012$1,669.06$16,618$2,723.68+$5.4KAAPGV
6$25,359$1,806.01$20,263$3,993.80+$5.1KAAPGV
7$29,078$1,944.49$25,936$6,098.36+$3.1KAAPGV
8← crossover$33,198$2,083.84$35,166$9,775.01$2.0KMO
9$37,745$2,223.40$51,026$16,597.78$13.3KMO
10$42,750$2,362.57$80,113$30,159.17$37.4KMO

AAPGV vs MO: Complete Analysis 2026

AAPGVStock

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Full AAPGV Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this AAPGV vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AAPGV vs SCHDAAPGV vs JEPIAAPGV vs OAAPGV vs KOAAPGV vs MAINAAPGV vs PMAAPGV vs BTIAAPGV vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.